New drug cocktail shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT04616183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adults will take part, and the study is currently active but no longer recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Experimental drug combo targets Hard-to-Treat GI cancers
- New combo aims to spare rectal cancer patients from surgery
- Wheat germ supplement studied for immune boost in advanced cancer
- Home monitoring may keep cancer patients out of the ER
- Intermittent fasting tested to ease radiation side effects in cancer patients